tiprankstipranks
JHS Svendgaard Laboratories Limited (IN:JHS)
:JHS
India Market
Want to see IN:JHS full AI Analyst Report?

JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

1 Followers

Top Page

IN:JHS

JHS Svendgaard Laboratories Limited

(JHS)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - Gpt-5.6Sol)
Rating:49Neutral
Price Target:
₹9.00
▲(21.46% Upside)
Action:Reiterated
Date:08/18/26
The score is primarily held back by weak financial performance—continued losses, margin pressure, and recurring negative operating/free cash flow—despite a solid low-leverage balance sheet. Technicals provide a partial offset with improving short- to mid-term momentum (above key moving averages and positive MACD), while valuation remains pressured due to negative earnings and no dividend support.
Positive Factors
Low Leverage
Very low leverage limits solvency pressure and interest burden, giving JHS greater financial flexibility to manage operating volatility and invest in production capacity without relying heavily on additional borrowing.
Negative Factors
Persistent Losses
Continued net and operating losses show that the business has not yet converted revenue into sustainable shareholder returns. This limits internal funding capacity and leaves profitability dependent on meaningful margin and cost improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits solvency pressure and interest burden, giving JHS greater financial flexibility to manage operating volatility and invest in production capacity without relying heavily on additional borrowing.
Read all positive factors

JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description
JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive prod...
How the Company Makes Money
JHS primarily makes money by manufacturing and supplying finished consumer products (notably oral care products such as toothpaste) to customers and receiving revenue from the sale of those goods. A key revenue stream is typically contract manufac...

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary
Financials are constrained by ongoing losses and weak cash generation. Despite FY2026 revenue recovery (+8.7%) and improved profitability versus FY2025, the company remains loss-making with negative operating earnings and sharply lower gross margin. The balance sheet is a relative strength with low leverage (debt-to-equity ~0.09), but recurring negative operating cash flow and negative free cash flow in FY2026 keep overall financial performance weak.
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
BreakdownMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.02B919.97M698.06M840.82M854.91M
Gross Profit177.22M309.55M203.55M165.45M201.68M
EBITDA60.64M-39.92M33.78M-163.82M85.45M
Net Income-19.22M-197.44M-40.58M-175.17M-40.52M
Balance Sheet
Total Assets2.15B2.01B1.97B2.28B2.22B
Cash, Cash Equivalents and Short-Term Investments191.00M200.16M94.56M386.51M80.19M
Total Debt148.51M64.58M51.29M155.09M61.82M
Total Liabilities405.49M284.41M271.70M543.87M269.46M
Stockholders Equity1.75B1.73B1.70B1.74B1.86B
Cash Flow
Free Cash Flow-148.91M-157.11M-401.17M89.43M-158.75M
Operating Cash Flow-20.97M-51.78M-85.84M232.86M-91.36M
Investing Cash Flow-130.38M-220.18M-217.34M96.77M-46.97M
Financing Cash Flow121.43M232.97M21.74M-9.00M-16.72M

JHS Svendgaard Laboratories Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.41
Price Trends
50DMA
7.89
Positive
100DMA
8.31
Negative
200DMA
9.13
Negative
Market Momentum
MACD
0.21
Positive
RSI
47.73
Neutral
STOCH
37.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 7.41 is below the 20-day moving average (MA) of 8.44, below the 50-day MA of 7.89, and below the 200-day MA of 9.13, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 37.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
₹166.59B22.123.38%2.82%-8.52%
69
Neutral
₹153.48B61.5221.08%237.19%
67
Neutral
₹497.92B36.872.30%3.79%-3.28%
65
Neutral
₹682.97B34.711.95%7.40%10.63%
59
Neutral
₹934.74B48.901.89%9.22%3.19%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
49
Neutral
₹730.71M-37.6819.41%89.58%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:JHS
JHS Svendgaard Laboratories Limited
8.16
-2.75
-25.21%
IN:COLPAL
Colgate-Palmolive (India) Limited
1,854.00
-453.95
-19.67%
IN:DABUR
Dabur India Limited
383.15
-130.98
-25.48%
IN:EMAMILTD
Emami Limited
364.00
-207.10
-36.26%
IN:GODREJCP
Godrej Consumer Products Limited
903.00
-330.57
-26.80%
IN:HONASA
Honasa Consumer Limited
480.85
183.75
61.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 18, 2026